Miettinen T A, Färkkilä M, Vuoristo M, Karvonen A L, Leino R, Lehtola J, Friman C, Seppälä K, Tuominen J
Second Department of Medicine, University of Helsinki, Finland.
Hepatology. 1995 May;21(5):1261-8.
A randomized placebo-controlled 2-year study was performed in 69 patients with primary biliary cirrhosis (PBC) on serum lipids during ursodeoxycholic acid (URSO) and colchicine treatments. In addition to serum bilirubin and alkaline phosphatase (AFOS), two variables considered to reflect liver function, serum lipoproteins, cholesterol precursors (squalene, delta 8-cholestenol, lathosterol and desmosterol), markers of cholesterol synthesis, cholestanol and plant sterols (campesterol and sitosterol), markers of liver function and cholesterol absorption, were studied before and during the treatments. Serum bilirubin was inconsistently improved by URSO, whereas improvement of AFOS values was better by URSO than colchicine, especially in patients with initially more advanced PBC. Serum total cholesterol was reduced by both drugs, very low-density lipoprotein (VLDL) and high-density lipoprotein (HDL) cholesterol by URSO. Cholesterol precursor sterols were increased by both URSO and colchicine mainly in patients with initially less severe PBC. On the other hand, the cholestanol values were markedly increased initially, and the values were related to bilirubin during the 2-year period, were further increased in the placebo group, and reduced in the URSO and colchicine groups, so that the improvement was highest in the URSO-treated patients with the severe form of PBC. The increase of the serum plant sterols, particularly that of sitosterol, was retarded by the two drugs so that the campesterol/sitosterol ratio, which was related to serum bilirubin, was increased especially in the cases with initially more advanced PBC.(ABSTRACT TRUNCATED AT 250 WORDS)
对69例原发性胆汁性肝硬化(PBC)患者进行了一项为期2年的随机安慰剂对照研究,观察熊去氧胆酸(URSO)和秋水仙碱治疗期间血清脂质的变化。除了血清胆红素和碱性磷酸酶(AFOS)这两个被认为反映肝功能的指标外,还在治疗前和治疗期间研究了血清脂蛋白、胆固醇前体(角鲨烯、δ8-胆甾烯醇、羊毛甾醇和链甾醇)、胆固醇合成标志物、胆甾烷醇和植物甾醇(菜油甾醇和谷甾醇),这些也是肝功能和胆固醇吸收的标志物。URSO对血清胆红素的改善并不一致,而URSO对AFOS值的改善优于秋水仙碱,尤其是在初始病情较重的PBC患者中。两种药物均可降低血清总胆固醇,URSO可降低极低密度脂蛋白(VLDL)和高密度脂蛋白(HDL)胆固醇。URSO和秋水仙碱均可使胆固醇前体甾醇增加,主要发生在初始病情较轻的PBC患者中。另一方面,胆甾烷醇值最初显著升高,且在2年期间与胆红素相关,在安慰剂组中进一步升高,而在URSO和秋水仙碱组中降低,因此在病情严重的PBC患者中,接受URSO治疗的患者改善最为明显。两种药物均延缓了血清植物甾醇的增加,尤其是谷甾醇,因此与血清胆红素相关的菜油甾醇/谷甾醇比值升高,尤其是在初始病情较重的患者中。(摘要截选至250字)